Semaglutide 2.4 mg Weekly Investigated for Obesity and Prediabetes Management

Obesity and prediabetes are growing global health concerns, significantly increasing the risk of developing serious conditions like type 2 diabetes and cardiovascular disease. While lifestyle interventions are foundational, pharmacological treatments are often necessary to achieve sustainable weight loss and glycemic control. Current research seeks to identify highly effective and safe therapeutic options. This Phase 3 clinical trial was designed to specifically evaluate the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg in promoting weight loss and reversing prediabetes in adults living with both conditions.

The study's primary objective was to assess the effectiveness of semaglutide 2.4 mg in inducing significant weight loss and achieving normoglycemia (normal blood sugar levels) in participants with prediabetes. While specific quantitative results detailing the percentage of weight loss or the rate of prediabetes reversal are not provided in this summary, the trial was designed to rigorously measure these outcomes. The 52-week treatment period allowed for a comprehensive evaluation of both short-term and sustained effects. > The study aimed to demonstrate that semaglutide 2.4 mg once-weekly, combined with lifestyle interventions, could lead to a clinically meaningful reduction in body weight and a higher rate of prediabetes resolution compared to placebo. The 207 participants provided a robust sample size for evaluating the safety profile and efficacy trends of the 2.4 mg dose. The trial also monitored for adverse events to establish the overall safety and tolerability of the intervention over the 52-week duration.